Pulmonary Arterial Hypertension
Conditions
Brief summary
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study. The primary objective of this non-interventional follow-up study is to assess the long-term real-world clinical outcomes, including disease progression and survival rates, in patients who initially participated in and completed the randomized TripleTRE trial. Planned observation duration per patient is a minimum of 3 years.
Interventions
None listed
Sponsors
AOP Orphan Pharmaceuticals AG
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1\. Patients previously participating in the randomized TripleTRE trial who are able and willing to provide a signed informed consent for study participation in NIS
Exclusion criteria
1. Lost to follow-up patients of TripleTRE study 2. Patients who discontinued all medicinal PAH treatments (e.g. after successful lung transplantation) 3. Patients who withdrew from the initial TripleTRE trial due to significant non-compliance with trial requirements (not adhering to therapy, not coming to hospital visits)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to first clinical worsening | up to year 3 | clinical worsening is defined as fulfilling on of the following criteria: * PAH related death (including all deaths where PAH cannot be excluded as cause) * Lung transplantation due to PAH * PAH-related hospitalization * Post baseline decrease in 6MWD by 15% * Post baseline worsening of WHO FC |
| Time to death or lung transplantation | up to year 3 | — |
| Total number of clinical worsenings | up to year 3 | clinical worsening is defined as fulfilling on of the following criteria: * PAH related death (including all deaths where PAH cannot be excluded as cause) * Lung transplantation due to PAH * PH-related hospitalization * Post baseline decrease in 6MWD by 15% * Post baseline worsening of WHO FC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Long-term change in 6MWD | up to year 3 | 6-Minute Walking Distance (6MWD) will be measured in meters |
| Long-term change in PAH treatment regimens | up to year 3 | any change or addition of new PH medication including dosing in time |
| Long-term change in risk status | up to year 3 | Risk status measured by simplified four-strata risk-assessment tool |
| Long-term change in WHO FC | up to year 3 | World Health Organization Functional Class (WHO FC) is categorized from I (no symptoms) to IV (severe dyspnea and symptoms) |
| Long-term change in BDS | up to year 3 | BDS - Borg Dyspnea Score, ranging from 0 (no exertion) to 10 (maximum) |
| Long-term change in NT-proBNP/BNP | up to year 3 | NT-proBNP/BNP: N-terminal pro Brain Natriuretic Peptide |
| Long-term change in Pulmonary Vascular Resistance (PVR) | up to year 3 | PVR to be measured in WU Parameter will be collected according to clinical routine |
| Long-term change in mean Pulmonary Arterial Pressure (mPAP) | up to year 3 | mPAP to be measured in mmHg Parameter will be collected according to clinical routine |
| Long-term change in mean Right Atrial Pressure (mRAP) | up to year 3 | mean Right Atrial Pressure (mRAP) to be measured in mmHg Parameter will be collected according to clinical routine |
| Long-term change in Cardiac Index (CI) | up to year 3 | Cardiac index (CI) measured in liters per minute per square meter Parameter will be collected according to clinical routine |
| Long-term change in Cardiac Output (CO) | up to year 3 | Cardiac output (CO) measured in liters per minute Parameter will be collected according to clinical routine |
| Long-term change in Pulmonary capillary wedge pressure (PCWP) | up to year 3 | Pulmonary capillary wedge pressure (PCWP) measured in mmHg Parameter will be collected according to clinical routine |
| Long-term change in Stroke volume index (SVI) | up to year 3 | Parameter will be collected according to clinical routine |
| Long-term change in RV-PA coupling | up to year 3 | RV-PA coupling estimated by the ratio of tricuspid annular plane systolic excursion by pulmonary artery systolic pressure Parameter will be collected according to clinical routine |
| Long-term change in RV fractional area change (RVFAC) | up to year 3 | RV fractional area change (RVFAC) calculated in % Parameter will be collected according to clinical routine |
| Long-term change in Right Atrium (RA) area | up to year 3 | Right Atrium (RA) area in square centimeters Parameter will be collected according to clinical routine |
| Long-term change in Pericardial effusion | up to year 3 | Pericardial effusion assessment will be done and rated as yes/no Parameter will be collected according to clinical routine |
| Long-term change in Right ventricular ejection fraction (RVEF) | up to year 3 | Parameter will be collected according to clinical routine |
| Long-term change in Right Atrial Pressure (RAP) | up to year 3 | RAP to be measured in mmHg Parameter will be collected according to clinical routine |
| Long-term change in RV end-diastolic area (RVEDA) | up to year 3 | RV end-diastolic area (RVEDA) measured in square centimeters Parameter will be collected according to clinical routine |
| Long-term change in RV end-systolic area (RVESA) | up to year 3 | RV end-systolic area (RVESA) measured in square centimeters Parameter will be collected according to clinical routine |
Other
| Measure | Time frame | Description |
|---|---|---|
| Frequency and seriousness of adverse events (AE) and adverse drug reactions (ADR) | up to year 3 | This includes: * Adverse events (S)AEs * Adverse drug reactions (S)ADRs related to any of PAH treatments * Adverse events related to underlying diagnosis, PAH |
| Long-term change in QoL using PAH-specific emPHasis-10 questionnaire | up to year 3 | Emphasis meaning something of special importance or significance. Please translate using the most appropriate term. The PH in emPHasis represents the condition Pulmonary Hypertension. The number 10 refers to the number of items in the questionnaire. This questionnaire is designed to determine how Pulmonary Hypertension (PH) affects patient's life. It refers to how PH affects or the impact that PH has on the patient's life. |
| Long-term change in QoL using European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) questionnaire | up to year 3 | The EQ-5D-5L questionnaire consists of 2 parts - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. It should be noted that the numerals 1-5 have no arithmetic properties and should not be used as a cardinal score. |
Countries
Austria, Czechia, France, Germany, Hungary, Italy, Poland, Romania, Spain
Outcome results
None listed